Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health

U.S. drugstore chain operators Walgreens Boots Alliance and CVS Health Corp said on Friday they were forced to temporarily shut some stores due to staffing issues triggered by the latest surge in COVID-19 infections.

Walgreens, CVS shut some stores as Omicron variant complicates staffing issues

Walgreens and CVS said they are unable to quantify weekend closures, which fluctuate each week and sometimes occur without much notice.

Walgreens and CVS shut some pharmacies on weekends amid staffing strains

Walgreens is making several acquisitions in the healthcare market and recently bought a majority stake in VillageMD and CareCentrix. Management is expecting growth in the double digits from fiscal 2025 going forward.

Walgreens Boots Alliance: An Almost Perfect Bet

Target

Use these stocks to fight inflation or just to help pay your bills.

2 Cheap Dividend Aristocrats You Can Buy and Hold for Decades

Bain Capital and CVC Capital Partners are putting together a multibillion-pound joint bid for pharmaceutical giant Boots, according to multiple reports Tuesday (Jan. 11). Boots has more than 2,000 stores and more than 50,000 employees around the world.

Report: British Private Equity Firm CVC Joins Bain Capital in Joint Bid for Walgreens Boots Unit

The review comes as Walgreens pushes deeper into healthcare. Private equity groups are touted as the most likely buyers of the business.

Walgreens Begins Strategic Review of Boots Drugstore Business

Buyout giants Bain Capital and CVC Capital are preparing a joint bid for high street chemist Boots, according to news reports. Boots owner Walgreens Boots Alliance Inc (NASDAQ:WBA) (WBA) has announced a strategic review of the UK business as part of its move to focus on US healthcare.

Bain Capital and CVC to make joint bid for Boots - reports

Walgreens Boots Alliance, Inc. (WBA) CEO Roz Brewer Presents at 40th Annual JPMorgan Virtual Healthcare Conference (Transcript)

Walgreens Boots Alliance Inc has begun a strategic review of its U.K.-based Boots business, Chief Executive Officer Rosalind Brewer said on Tuesday, as the second largest U.S. pharmacy chain tries to renew its focus on U.S. healthcare.

Walgreens starts strategic review for UK-based Boots business

Walgreens Boots Alliance has begun a strategic review of its Boots business.

Walgreens CEO says company is looking into strategic options for U.K.-based Boots business

With COVID-19 infections reaching peak levels, Walgreens Boots Alliance Inc. should get a boost from demand for vaccine administration and at-home testing, Mizuho analysts say.

The Ratings Game: Walgreens should get a boost from omicron, home testing demand and pediatric vaccines, analysts say

Currently part of the U.S./U.K. group Walgreens Boots Alliance (WBA), an auction of Boots appears increasingly likely this spring, representing one of the biggest U.K. retail deals for many years.

Private Equity Ready To Swoop As Walgreens Mulls Sale Of Boots

The pharmacy stock's high dividend yield and cheap valuation are attractive during Fed tapering.

Here's Why Walgreens Stock Jumped 16.4% in December

"This is not petty theft," CEO Roz Brewer said on an investor call. "These are gangs that actually go in and empty our stores of beauty products."

Walgreens executives say the drugstore chain is losing 50% more money due to loss and theft

Apple

Datadog

Coca-Cola

NXP Semiconductors

QUALCOMM

Visa

Verizon

The major benchmarks started the year on a high note , with bank and tech sectors leading the charge.

Tech Selloff Highlights Choppy First Week of 2022

Option activity after earnings suggest that traders are optimistic about Walgreens Boots Alliance (WBA) stock.

Walgreens Boots Alliance (WBA) Option Traders Still See Upside

Walgreens will have more than 160 doctor-staffed Village Medical clinics open by the end of this year.

Walgreens Will Open 160 Village Medical Clinics By Year's End

Beyond Meat

SoFi Technologies

Meta, SoFi Technologies, Walgreens Boots Alliance and Beyond Meat were our top stock trades for Friday. Now, let's get a look at the charts.

4 Top Stock Trades for Friday: FB, SOFI, WBA, BYND

Walgreens Boots' (WBA) revenues increased year over year in the fiscal first quarter, driven by COVID-19 vaccinations and testing.

Walgreens Boots (WBA) Q1 Earnings Top Estimates, 2022 View Up

Walgreens Boots Alliance, Inc. (WBA) CEO Ros Brewer on Q1 2022 Results - Earnings Call Transcript

The second-largest U.S. pharmacy retailer says it plans to open 100 new Walgreens Health Corner locations this year, having closed two acquisitions last quarter and now finalizing a third. While no fresh details were given concerning the sale of its U.K.-based Boots franchise, sharply improved international results would certainly make a deal easier and more […]

Walgreens Focused on Growing Health Unit as Solid Int'l Results Complicate Sale of Boots Unit

The shares of blue chip Walgreens Boots Alliance Inc (NASDAQ: WBA) are down 2.4% to trade at $52.69 at last check, despite the retailer beating top- and bottom-line estimates for its  fiscal first quarter.

Blue-Chip Retail Stock Falls Despite Beat-and-Raise

Walgreens Boots Alliance Inc (NASDAQ: WBA) was initially trading higher, but is now trading lower after the company announced better-than-expected first-quarter fiscal 2022 financial results and increased full-year guidance.  Walgreens reported quarterly earnings of $1.68 per share, which beat the estimate of $1.33 per share.

What's Going On With Walgreens Shares Today?

Walgreens (WBA) delivered earnings and revenue surprises of 24.44% and 2.71%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Surpasses Q1 Earnings and Revenue Estimates

Walgreens Boots Alliance reported more than $3.5 billion in quarterly profits thanks in part to a rush of customers being vaccinated against Covid-19 or tested for the virus as the Omicron virus surges around the world.

News for Walgreens Stock (WBA)